Menu Search
Equities

Kuros Biosciences AG

0RHR:LSE

Kuros Biosciences AG

Actions
  • Price (CHF)28.17
  • Today's Change-0.283 / -0.99%
  • Shares traded6.20k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Nov 08 2024 17:19 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CHFIncome statement in CHFView more

Year on year Kuros Biosciences AG grew revenues 86.61% from 17.99m to 33.56m while net income improved from a loss of 14.60m to a smaller loss of 13.73m.
Gross margin79.13%
Net profit margin-16.91%
Operating margin-17.55%
Return on assets-11.42%
Return on equity-14.32%
Return on investment-13.53%
More ▼

Cash flow in CHFView more

In 2023, cash reserves at Kuros Biosciences AG fell by 9.86m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 8.84m for operations while cash used for investing totalled 326.00k.
Cash flow per share-0.2068
Price/Cash flow per share--
Book value per share1.64
Tangible book value per share0.524
More ▼

Balance sheet in CHFView more

Kuros Biosciences AG has a Debt to Total Capital ratio of 8.47%, a higher figure than the previous year's 3.58%.
Current ratio2.73
Quick ratio2.17
Total debt/total equity0.0925
Total debt/total capital0.0847
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.